Fast Take InSilico Medicine Cayman

Research evidence excerpt

Fast Take InSilico Medicine Cayman

Forecast returns

Forecast price appreciation 79.5%

Forecast dividend yield 0.0%

Forecast stock return 79.5%

Market return assumption 8.1%

Forecast excess return 71.3%

Company Description

Founded in 2014 and headquartered in the US, InSilico is a globally leading AI-driven drug

discovery (AIDD) company that utilises its end-to-end proprietary Pharma.AI platform for drug

discovery and pipeline development (86.8% of 2025 total revenue). Other segments include

software solutions and other discovery, accounting for 8.7% and 4.4% of 2025 revenue.

Valuation Method and Risk Statement

We value InSilico Medicine using a risk-adjusted DCF methodology.

We believe the key downside risks include: 1) termination or material scaling back of its major

partnerships, which could reduce milestone income and weaken external validation of its AI

platform; 2) clinical failure or delays of core pipeline assets, particularly those serving as key

proof-of-concept for its AI driven discovery approach; 3) tighter regulatory requirements

related to AIDD operations and partnerships, which could increase compliance costs, extend

development timelines and dampen partner engagement; 4) uncertainty in the timing and

probability of drug discovery collaboration revenue, which may lead to weaker-than-expected

revenue in the near term; 5) failing to achieve out-licensing deals consistently as expected,

which could adversely affect the company's cash flow; 6) intense competition with

biopharma companies that develop in-house AIDD capability and technology companies; and

7) technological obsolescence risk, if the company is unable to rapidly adapt to the latest

scientific and technological changes and pharmaceutical market changes.

InSilico Medicine Cayman 29 July 2026 ab 2